{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T10:20:46Z","timestamp":1772792446154,"version":"3.50.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"vor","delay-in-days":28,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Cogence Health DWC LLC"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-026-12773-1","type":"journal-article","created":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T08:58:12Z","timestamp":1770368292000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cytomegalovirus reactivation prevention and treatment post-hematopoietic stem cell transplantation: a Delphi study in four Gulf cooperation council countries"],"prefix":"10.1186","volume":"26","author":[{"given":"Jo\u00e3o Antonio Goncalves Garreta","family":"Prats","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khalil Al","family":"Farsi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Murtadha","family":"Al-Khabori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nameer","family":"Al-Saadawi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salem H.","family":"Alshemmari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Honar","family":"Cherif","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dima","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Panayotis","family":"Kaloyannidis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert Lodu Serafino Wani","family":"Swaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,6]]},"reference":[{"key":"12773_CR1","doi-asserted-by":"publisher","first-page":"171","DOI":"10.4103\/EJH.EJH_89_23","volume":"49","author":"A Mohsen","year":"2024","unstructured":"Mohsen A, Fahmy O, Azmy E, Denewer M. Comparative analysis of the impact of cytomegalovirus viremia between fully matched and haploidentical hematopoietic stem cell transplants in acute leukemia patients. Egypt J Haematol. 2024;49:171\u20136. https:\/\/doi.org\/10.4103\/EJH.EJH_89_23.","journal-title":"Egypt J Haematol"},{"key":"12773_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S12985-024-02421-Y","volume":"21","author":"HY AlQahtani","year":"2024","unstructured":"AlQahtani HY, AlSuhebany N, Alowais SA, AlShehri B, Althemery A, Alghanim A, et al. Characterization of recurrent cytomegalovirus reactivations post allogenic stem cell transplantation in a population with high seropositivity. Virol J 2024. 2024;21:1. https:\/\/doi.org\/10.1186\/S12985-024-02421-Y.","journal-title":"Virol J 2024"},{"key":"12773_CR3","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1038\/bmt.2013.1","volume":"48","author":"A Bazarbachi","year":"2013","unstructured":"Bazarbachi A, Labopin M, Ghavamzadeh A, Giebel S, Al-Zahrani H, Ladeb S, et al. Allogeneic matched-sibling hematopoietic cell transplantation for AML: comparable outcomes between Eastern mediterranean (EMBMT) and European (EBMT) centers. Bone Marrow Transpl. 2013;48:1065\u20139.","journal-title":"Bone Marrow Transpl"},{"key":"12773_CR4","doi-asserted-by":"publisher","first-page":"63","DOI":"10.4103\/2279-042X.176554","volume":"5","author":"B Valadkhani","year":"2016","unstructured":"Valadkhani B, Kargar M, Ashouri A, Hadjibabaie M, Gholami K, Ghavamzadeh A. The risk factors for cytomegalovirus reactivation following stem cell transplantation. J Res Pharm Pract. 2016;5:63\u20139. https:\/\/doi.org\/10.4103\/2279-042X.176554.","journal-title":"J Res Pharm Pract"},{"key":"12773_CR5","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1038\/sj.bmt.1705265","volume":"11","author":"M Ramzi","year":"2009","unstructured":"Ramzi M. Hematopoietic stem cell transplantation in Southern iran: History, current status and future direction. Iran Red Crescent Med J. 2009;11:364\u201370. https:\/\/doi.org\/10.1038\/sj.bmt.1705265.","journal-title":"Iran Red Crescent Med J"},{"key":"12773_CR6","doi-asserted-by":"publisher","unstructured":"Farsi F, Al MK, Al, Alawi FB, Al-Khabori M, Dennison D, Busaidi A, Al, et al. Cytomegalovirus infection post-hematopoietic stem cell transplant: incidence, risk factors, and outcome in an Omani cohort. Oman Med J. 2023;38. https:\/\/doi.org\/10.5001\/OMJ.2023.113.","DOI":"10.5001\/OMJ.2023.113"},{"key":"12773_CR7","first-page":"521","volume":"29","author":"R Iftikhar","year":"2023","unstructured":"Iftikhar R, Farhan M, Khan M, Ghafoor T, Shahbaz N, Khan MA, et al. Cytomegalovirus infection Post-Allogeneic stem cell transplantation: experience from a country with high seropositivity. Transpl Cell Ther. 2023;29:521\u2013e1.","journal-title":"Transpl Cell Ther"},{"key":"12773_CR8","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.jtct.2021.05.001","volume":"27","author":"M Hakki","year":"2021","unstructured":"Hakki M, Aitken SL, Danziger-Isakov L, Michaels MG, Carpenter PA, Chemaly RF, et al. Series: #3\u2014Prevention of cytomegalovirus infection and disease after hematopoietic cell transplantationamerican society for transplantation and cellular therapy. Transpl Cell Ther. 2021;27:707\u201319. https:\/\/doi.org\/10.1016\/j.jtct.2021.05.001.","journal-title":"Transpl Cell Ther"},{"key":"12773_CR9","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1097\/QCO.0000000000001065","volume":"37","author":"VZ Zhu","year":"2024","unstructured":"Zhu VZ, Horton MB, Haeusler GM, Yong MK. The emergence of letermovir and maribavir drug-resistant mutations: from clinical trials to real-world studies. Curr Opin Infect Dis. 2024;37:536\u201346. https:\/\/doi.org\/10.1097\/QCO.0000000000001065.","journal-title":"Curr Opin Infect Dis"},{"key":"12773_CR10","doi-asserted-by":"publisher","unstructured":"Ljungman P, Alain S, Chemaly RF, Einsele H, Galaverna F, Hirsch HH, et al. Recommendations from the 10th European Conference on Infections in Leukaemia for the management of cytomegalovirus in patients after allogeneic haematopoietic cell transplantation and other T-cell-engaging therapies. Lancet Infect Dis. 2025;25:e451\u201362. https:\/\/doi.org\/10.1016\/S1473-3099(25)00069-6.","DOI":"10.1016\/S1473-3099(25)00069-6"},{"key":"12773_CR11","doi-asserted-by":"publisher","unstructured":"Cesaro S, Spadea M, Fagioli F, Porta F, Rabusin M, Ferrando G, et al. Expert consensus on the management of cytomegalovirus infection in pediatric allogeneic hematopoietic stem cell transplantation. Curr Res Transl Med. 2025;73. https:\/\/doi.org\/10.1016\/j.retram.2025.103535.","DOI":"10.1016\/j.retram.2025.103535"},{"key":"12773_CR12","doi-asserted-by":"publisher","unstructured":"Pi\u00f1ana JL, Gim\u00e9nez E, V\u00e1zquez L, Marcos M\u00c1, Guerreiro M, Duarte R, et al. Update on cytomegalovirus infection management in allogeneic hematopoietic stem cell transplant recipients. A consensus document of the Spanish group for hematopoietic transplantation and cell therapy (GETH-TC). Mediterr J Hematol Infect Dis. 2024;16. https:\/\/doi.org\/10.4084\/MJHID.2024.065.","DOI":"10.4084\/MJHID.2024.065"},{"key":"12773_CR13","doi-asserted-by":"publisher","first-page":"e70255","DOI":"10.1111\/CTR.70255","volume":"39","author":"C Girmenia","year":"2025","unstructured":"Girmenia C, Lazzarotto T, Martino M, Bonifazi F, Baldanti F, Clerici P, et al. Management of cytomegalovirus infection in allogeneic hematopoietic stem cell and in solid organ transplantation: updated recommendations by the GITMO, SITO, SIMIT, and AMCLI Italian societies. Clin Transpl. 2025;39:e70255. https:\/\/doi.org\/10.1111\/CTR.70255.","journal-title":"Clin Transpl"},{"key":"12773_CR14","doi-asserted-by":"publisher","unstructured":"Khawaja F, Zamora D, Yong MK, Hakki M, Goscicki BK, Danziger-Isakov L, et al. American Society for Transplantation and Cellular Therapy Series #11: updated cytomegalovirus guidelines in hematopoietic cell transplant and cellular therapy recipients. Transplant Cell Ther. 2025;31:727\u201341. https:\/\/doi.org\/10.1016\/J.JTCT.2025.06.025.","DOI":"10.1016\/J.JTCT.2025.06.025"},{"key":"12773_CR15","doi-asserted-by":"publisher","unstructured":"Mana H, Al, Yassine HM, Younes NN, Al-Mohannadi A, Al-Sadeq DW, Alhababi D, et al. The current status of cytomegalovirus (CMV) prevalence in the MENA region: a systematic review. Pathogens. 2019;8. https:\/\/doi.org\/10.3390\/pathogens8040213.","DOI":"10.3390\/pathogens8040213"},{"key":"12773_CR16","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","volume":"310","author":"WM Association","year":"2013","unstructured":"Association WM. World medical association declaration of helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310:2191\u20134. https:\/\/doi.org\/10.1001\/jama.2013.281053.","journal-title":"JAMA"},{"key":"12773_CR17","doi-asserted-by":"publisher","unstructured":"Hwang D-K, Ng DSC, Qian Z, Agrawal R, Chan ASY, Chhablani J, et al. International consensuses and guidelines on diagnosing and managing cytomegalovirus (CMV) retinitis by the Asia-Pacific Vitreo-retina society (APVRS), the Asia-Pacific Professors of Ophthalmology (AAPPO) and the Asia-Pacific Society of Ocular Inflammation and Infection (APSOII). Asia-Pacific J Ophthalmol. 2025;100248. https:\/\/doi.org\/10.1016\/j.apjo.2025.100248.","DOI":"10.1016\/j.apjo.2025.100248"},{"key":"12773_CR18","doi-asserted-by":"publisher","unstructured":"Kotton CN. CMV: Prevention, diagnosis and therapy. Am J Transplant. 2013;13(SUPPL 3):24\u201340. https:\/\/doi.org\/10.1111\/AJT.12006.","DOI":"10.1111\/AJT.12006"},{"key":"12773_CR19","doi-asserted-by":"publisher","first-page":"e127","DOI":"10.1016\/S2352-3026(23)00344-7","volume":"11","author":"D Russo","year":"2024","unstructured":"Russo D, Schmitt M, Pilorge S, Stelljes M, Kawakita T, Teal VL, et al. Efficacy and safety of extended duration letermovir prophylaxis in recipients of Haematopoietic stem-cell transplantation at risk of cytomegalovirus infection: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Haematol. 2024;11:e127\u201335.","journal-title":"Lancet Haematol"},{"key":"12773_CR20","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.3390\/V15091884","volume":"15","author":"D Nho","year":"2023","unstructured":"Nho D, Lee R, Cho SY, Lee DG, Kim EJ, Park S, et al. Cytomegalovirus infection after allogeneic hematopoietic cell transplantation under 100-Day letermovir prophylaxis: A Real-World 1-Year Follow-Up study. Viruses. 2023;15:1884. https:\/\/doi.org\/10.3390\/V15091884.","journal-title":"Viruses"},{"key":"12773_CR21","doi-asserted-by":"crossref","unstructured":"Zamora D, Duke ER, Xie H, Edmison BC, Akoto B, Kiener R, et al. Cytomegalovirus-specific T-cell reconstitution following letermovir prophylaxis after hematopoietic cell transplantation. 2021.","DOI":"10.1182\/blood.2020009396"},{"key":"12773_CR22","doi-asserted-by":"publisher","first-page":"107537","DOI":"10.1016\/J.IJANTIMICAG.2025.107537","volume":"66","author":"K Lynch","year":"2025","unstructured":"Lynch K, M\u00e4rtson AG. The importance of drug exposure in the development of cytomegalovirus resistance. Int J Antimicrob Agents. 2025;66:107537. https:\/\/doi.org\/10.1016\/J.IJANTIMICAG.2025.107537.","journal-title":"Int J Antimicrob Agents"},{"key":"12773_CR23","doi-asserted-by":"publisher","first-page":"3311","DOI":"10.1128\/JCM.00797-08","volume":"46","author":"C Gimeno","year":"2008","unstructured":"Gimeno C, Solano C, Latorre JC, Hern\u00e1ndez-Boluda JC, Clari MA, Remigia MJ, et al. Quantification of DNA in plasma by an automated real-time PCR assay (cytomegalovirus PCR kit) for surveillance of active cytomegalovirus infection and guidance of preemptive therapy for allogeneic hematopoietic stem cell transplant recipients. J Clin Microbiol. 2008;46:3311\u20138.","journal-title":"J Clin Microbiol"},{"key":"12773_CR24","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/sj.bmt.1703513","volume":"29","author":"K Yakushiji","year":"2002","unstructured":"Yakushiji K, Gondo H, Kamezaki K, Shigematsu K, Hayashi S, Kuroiwa M, et al. Monitoring of cytomegalovirus reactivation after allogeneic stem cell transplantation: comparison of an antigenemia assay and quantitative real-time polymerase chain reaction. Bone Marrow Transpl. 2002;29:599\u2013606.","journal-title":"Bone Marrow Transpl"},{"key":"12773_CR25","unstructured":"Department of Clinical Haematology, Oxford BMT\/IEC Programme. Management of cytomegalovirus (CMV) reactivation and infection in allogeneic blood and marrow transplant (BMT) recipients. Oxford: Oxford University Hospitals NHS; 2024 Sep. p. 1\u201314."},{"key":"12773_CR26","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1097\/TP.0b013e3181ff8719","volume":"91","author":"LF Lisboa","year":"2011","unstructured":"Lisboa LF, \u00c5sberg A, Kumar D, Pang X, Hartmann A, Preiksaitis JK, et al. The clinical utility of whole blood versus plasma cytomegalovirus viral load assays for monitoring therapeutic response. Transplantation. 2011;91:231\u20136.","journal-title":"Transplantation"},{"key":"12773_CR27","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1007\/s40265-018-0943-1","volume":"78","author":"A Meesing","year":"2018","unstructured":"Meesing A, Razonable RR. New developments in the management of cytomegalovirus infection after transplantation. Drugs. 2018;78:1085\u2013103.","journal-title":"Drugs"},{"key":"12773_CR28","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1056\/nejmoa1714656","volume":"381","author":"J Maertens","year":"2019","unstructured":"Maertens J, Cordonnier C, Jaksch P, Poir\u00e9 X, Uknis M, Wu J, et al. Maribavir for preemptive treatment of cytomegalovirus reactivation. N Engl J Med. 2019;381:1136\u201347. https:\/\/doi.org\/10.1056\/nejmoa1714656.","journal-title":"N Engl J Med"},{"key":"12773_CR29","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.jtct.2025.06.025","volume":"31","author":"F Khawaja","year":"2025","unstructured":"Khawaja F, Zamora D, Yong MK, Hakki M, Goscicki BK, Danziger-Isakov L, et al. American society for transplantation and cellular therapy series #11: updated cytomegalovirus guidelines in hematopoietic cell transplant and cellular therapy recipients. Transpl Cell Ther. 2025;31:727\u201341. https:\/\/doi.org\/10.1016\/j.jtct.2025.06.025.","journal-title":"Transpl Cell Ther"},{"key":"12773_CR30","first-page":"957","volume":"27","author":"MK Yong","year":"2021","unstructured":"Yong MK, Shigle TL, Kim Y-J, Carpenter PA, Chemaly RF, Papanicolaou GA. American society for transplantation and cellular therapy Series:# 4-Cytomegalovirus treatment and management of resistant or refractory infections after hematopoietic cell transplantation. Transpl Cell Ther. 2021;27:957\u201367.","journal-title":"Transpl Cell Ther"},{"key":"12773_CR31","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1093\/cid\/ciab988","volume":"75","author":"RK Avery","year":"2022","unstructured":"Avery RK, Alain S, Alexander BD, Blumberg EA, Chemaly RF, Cordonnier C, et al. Maribavir for refractory cytomegalovirus infections with or without resistance post-transplant: results from a phase 3 randomized clinical trial. Clin Infect Dis. 2022;75:690\u2013701.","journal-title":"Clin Infect Dis"},{"key":"12773_CR32","doi-asserted-by":"publisher","first-page":"e29609","DOI":"10.1002\/jmv.29609","volume":"96","author":"BG Schultz","year":"2024","unstructured":"Schultz BG, Kotton CN, Jutlla G, Ressa R, de Lacey T, Chowdhury E, et al. Cost-effectiveness of maribavir versus conventional antiviral therapies for post\u2010transplant refractory cytomegalovirus infection with or without genotypic resistance: A US perspective. J Med Virol. 2024;96:e29609.","journal-title":"J Med Virol"},{"key":"12773_CR33","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/ajt.12006","volume":"13","author":"CN Kotton","year":"2013","unstructured":"Kotton CN. CMV: prevention, diagnosis and therapy. Am J Transplant. 2013;13:24\u201340.","journal-title":"Am J Transplant"},{"key":"12773_CR34","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41409-022-01863-8","volume":"58","author":"S Cesaro","year":"2023","unstructured":"Cesaro S, Ljungman P, Tridello G, Mikulska M, Wendel L, Styczynski J, et al. New trends in the management of cytomegalovirus infection after allogeneic hematopoietic cell transplantation: a survey of the infectious diseases working Pary of EBMT. Bone Marrow Transpl. 2023;58:203\u20138. https:\/\/doi.org\/10.1038\/s41409-022-01863-8.","journal-title":"Bone Marrow Transpl"},{"key":"12773_CR35","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1016\/j.cmi.2023.03.020","volume":"29","author":"RR Razonable","year":"2023","unstructured":"Razonable RR. Oral antiviral drugs for treatment of cytomegalovirus in transplant recipients. Clin Microbiol Infect. 2023;29:1144\u20139.","journal-title":"Clin Microbiol Infect"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-026-12773-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-12773-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-12773-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T07:42:40Z","timestamp":1772782960000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-026-12773-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,6]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["12773"],"URL":"https:\/\/doi.org\/10.1186\/s12879-026-12773-1","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,6]]},"assertion":[{"value":"9 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors received honoraria from Cogence Health DWC LLC. Cogence Health DWC LLC received funding from Takeda Pharmaceutical Company Limited (Middle East) to facilitate this project. Dr. J Prats received grants from Merck Sharp & Dohme and consulting fees from Merck Sharp & Dohme, AbbVie, Libbs, and Pfizer, which also support him for attending meetings and\/or travel. Additionally, Dr. J Prats received payment\/honoraria from Europharma along with those from the other pharmaceutical companies listed above. Dr. M Al-Khabori received honoraria from Novartis, Pfizer, and SOBI. SOBI supports him for attending meetings and\/or travel. Dr. N Al-Saadawi received payment\/honoraria from Roche and SOBI. BIOLOGIX supports him for attending meetings and\/or travel. Dr. S Alshemmari received payment\/honoraria from Roche and AstraZeneca, and a research grant from MSD. Begien supports him for attending meetings and\/or travel. Dr. D Ibrahim, Dr. H Cherif, Dr. K Al Farsi, Dr. P Kaloyannidis, and Dr. R Swaka have no additional competing interest to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"498"}}